Ono and Medarex Enter Into Second Collaboration for the Development of a Fully Human Antibody Therapeutic
SDF-1 (Stromal cell-Derived Factor 1) is a member of the chemokine protein family whose members are involved in cell migration. SDF-1 has been implicated in a variety of diseases, and it is anticipated that blocking functions of SDF-1 could lead to uses in multiple therapeutic indications.
Under this collaboration, Ono and Medarex expect to jointly work toward potential commercialization of a fully human antibody. The two companies plan to share the costs and responsibilities of research and product development up to the completion of a Phase II clinical study. Thereafter, each company will be fully responsible for any continued development and any commercialization in its exclusive territory; Medarex's exclusive territory is North America, and Ono's exclusive territory is all areas outside of North America.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous